Cormedix Inc (CRMD) — Institutional Investor Activity (Q2 2026)

CRMD ranks #3075 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

195 institutions disclose a position in CRMD, but none treat it as a major bet — even Palisades Investment Partners, LLC, its most concentrated holder, allocates just 0.9% of its own portfolio to it.

Concurrent Investment Advisors, LLC has added to its CRMD position for two straight quarters, increasing it by $148.2K to reach $473.4K today.

CRMD is up 1.7% today, and institutions have been net buyers of $30.6M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

CRMD posted net income of $187.2M over the trailing twelve months, and currently trades at a P/E of 0.0.

• Profitable — net income of $187.2M over the trailing twelve months
• Net income improved year over year, from $51.2M to $187.2M
• Generated $175.0M in positive operating cash flow
• Current ratio of 2.11x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.04x equity — within a conventional range